Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Matthew Koshy; John L. Villano; Therese A. Dolecek; Andrew Howard; Usama Mahmood; Steven J. Chmura; Ralph R. Weichselbaum; Bridget J. McCarthy

doi:10.1007/s11060-011-0738-7

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Matthew Koshy, John L. Villano, Therese A. Dolecek, Andrew Howard, Usama Mahmood, Steven J. Chmura, Ralph R. Weichselbaum, Bridget J. McCarthy

Research output: Contribution to journal › Article › peer-review

274 Citations (SciVal)

Abstract

The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P<0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.

Original language	English
Pages (from-to)	207-212
Number of pages	6
Journal	Journal of Neuro-Oncology
Volume	107
Issue number	1
DOIs	https://doi.org/10.1007/s11060-011-0738-7
State	Published - Mar 2012

Bibliographical note

Funding Information:
Funding for Therese Dolecek and Bridget McCarthy was supported by the Central Brain Tumor Registry of the United States (CBTRUS) that receives support from the American Brain Tumor Association, the National Brain Tumor Society, the Pediatric Brain Tumor Foundation and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN261201000576P.

Keywords

Glioblastoma
Radiation
SEER
Temozolomide

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11060-011-0738-7

Cite this

@article{dd80af18c6294b75afcdd1cd0ab6b4c6,

title = "Improved survival time trends for glioblastoma using the SEER 17 population-based registries",

abstract = "The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P<0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.",

keywords = "Glioblastoma, Radiation, SEER, Temozolomide",

author = "Matthew Koshy and Villano, {John L.} and Dolecek, {Therese A.} and Andrew Howard and Usama Mahmood and Chmura, {Steven J.} and Weichselbaum, {Ralph R.} and McCarthy, {Bridget J.}",

note = "Funding Information: Funding for Therese Dolecek and Bridget McCarthy was supported by the Central Brain Tumor Registry of the United States (CBTRUS) that receives support from the American Brain Tumor Association, the National Brain Tumor Society, the Pediatric Brain Tumor Foundation and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN261201000576P.",

year = "2012",

month = mar,

doi = "10.1007/s11060-011-0738-7",

language = "English",

volume = "107",

pages = "207--212",

number = "1",

}

TY - JOUR

T1 - Improved survival time trends for glioblastoma using the SEER 17 population-based registries

AU - Koshy, Matthew

AU - Villano, John L.

AU - Dolecek, Therese A.

AU - Howard, Andrew

AU - Mahmood, Usama

AU - Chmura, Steven J.

AU - Weichselbaum, Ralph R.

AU - McCarthy, Bridget J.

N1 - Funding Information: Funding for Therese Dolecek and Bridget McCarthy was supported by the Central Brain Tumor Registry of the United States (CBTRUS) that receives support from the American Brain Tumor Association, the National Brain Tumor Society, the Pediatric Brain Tumor Foundation and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN261201000576P.

PY - 2012/3

Y1 - 2012/3

N2 - The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P<0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.

AB - The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P<0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.

KW - Glioblastoma

KW - Radiation

KW - SEER

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84861328546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861328546&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0738-7

DO - 10.1007/s11060-011-0738-7

M3 - Article

C2 - 21984115

AN - SCOPUS:84861328546

VL - 107

SP - 207

EP - 212

IS - 1

ER -

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this